21 марта 2016
During March 11-15 the European Society of Urology (EAU) Annual Congress was held in Munich, Germany. This conference is one of the most important events of the global urologist community.
Each year, more than 13 thousand members of the EAU meet to share the latest urologic expertise. The reports for workshops are thoroughly selected by independent expert committee consisting of industry opinion leaders. This time 4418 abstracts were submitted, whilst only 1268 passed the competition (29%).  
The representatives of First MSMU Chair of Urology and Research Institute of Uronefrology and Human Reproductive Health had the honour to present their findings, manifested by prof. M. Chalyi, junior researcher and co-authors M. Yepifanova and clinical intern S.Krasnov. This clinical study is being conducted in accordance with international standards of Good Clinical Practice (GCP) under the procedure of voluntary informed consent.  
The clinical study is being conducted within the agreement on scientific and technical cooperation between First MSMU and Central Clinical Hospital and Polyclinic. The personalized product is processed in terms of its quality and viability by Biomedical Technology Center.  
This paper dealing with application of the stromal-vascular fraction obtained from adipose tissue for treatment of erectile dysfunction has been represented in one of 90 workshops. The pilot project features 6 patients with erectile dysfunction not responding adequately to conventional therapies. Following the session, taking into account the scientific significance and topicality, this work has been recognized as the best. This was the first clinical study on the use of stem cells for this purpose, whilst previously the practices were limited to preclinical studies.  
The next EAU 2017 Congress to be held in London (United Kingdom) will face the ultimate project report.
про COVID-19